Following application of a topical formulation to the skin surface, the drug penetrates the stratum corneum, the uppermost layer of skin, and passes through the viable epidermis and dermis to reach the cutaneous vessels. Most drugs are taken up by these vessels to migrate to the systemic circulation, whereas a portion is further diffused into deeper tissues such as the subcutis and muscle. 1, 2) If the applied drug is a prodrug, a peptide or an oligonucleotide that can be readily metabolized in skin, its metabolism makes the skin disposition of the drug very difficult.
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Such dermato-pharmacokinetics have been analyzed by several in vitro and in vivo studies. 3, 4) Figure 1 schematically illustrates and compares the in vitro and in vivo skin dispositions of a drug and its metabolite after topical application. Overall skin permeations of the drug and its metabolites can be evaluated from the results of in vitro skin permeation experiments (Fig. 1a) . Information on enzyme distribution may be obtained by in vitro experiments using split or sliced layers of excised skin.
5) It is difficult, however, to determine the effects of the bloodstream on the drug disposition and metabolism in skin from in vitro methods. In contrast, body fluids and tissues are sampled for in vivo percutaneous absorption experiments (Fig. 1b) . It is possible to evaluate each fraction of the drug amount from the formulation to the systemic circulation or deeper skin tissues against the initial amount applied to skin. On the other hand, the time course of changes in the drug level in the skin tissues is not easy to follow due to difficulty in consecutive sampling, although some studies had achieved to give in-depth consideration for using multi-compartment model. 6, 7) In addition, the metabolic rate of a prodrug in the systemic circulation and the liver is generally so rapid that the metabolic rate in skin cannot be followed from the systemic pharmacokinetics. When such a prodrug is topically applied with the expectation of therapeutic effects after systemic absorption of its parent drug, the total (prodrugϩparent drug) amount permeated through the skin barrier, the stratum corneum, must be considered and the metabolism of the prodrug in skin is not important. 8) To target a prodrug or its parent drug into the cutaneous and muscular tissues below the site of application of a formulation, on the other hand, it is important to evaluate the skin disposition and metabolism of the materials.
Analysis of Skin Disposition and Metabolism of Ethyl
We have already evaluated the skin transport and metabolism of ethyl nicotinate (EN) as a model drug or prodrug primarily by in vitro methods. [8] [9] [10] [11] No clear relationship, however, was obtained between in vitro and in vivo metabolism in skin. This was probably due to a significant effect of cutaneous vessels on the in vivo profile or a large difference between in vivo and in vitro diffusion path lengths on skin metabolism. 12) We then planed to utilize an in situ hairless rat model in which an agar gel disc as a drug receptor was inserted in the abdomen. We have already reported such an in situ model with one agar gel disc in the rat abdomen, [13] [14] [15] and improved the model to a dual agar gel disc-inserted hairless rat model in which two agar gel discs were subcutaneously inserted in the abdominal region of rats, and a glass donor cell was placed on either side of the skin just above the implanted agar gel. 16) In the present study, an in situ dual agar gel disc-inserted hairless rat model was used to analyze the simultaneous transport and metabolism of EN in the skin (Fig. 1c) . The obtained results were compared to the in vitro and in vivo profiles. In Vitro Skin Permeation Experiment A vertical-type diffusion cell (effective diffusion area, 3.14 cm 2 ) with a water jacket was used for the in vitro skin permeation experiment. The water jacket was connected to a water bath at 37°C. Hairless rat skin was excised from the abdomen under anesthesia induced by i.p. injection of urethane. The obtained skin piece was immediately mounted on the receiver cell. EN solution (215 mmol/ml, 2.0 ml) was applied to the donor compartment (stratum corneum side), and the receiver compartment (dermis side) was filled with 16.0 ml of pH 7.4 phosphate-buffered saline (PBS). The receiver compartment was stirred with a magnetic bar throughout the experiment. At predetermined time intervals, samples (0.1 ml) were withdrawn from the receiver compartment for the assay and the same volume of fresh PBS was added to keep the volume constant. A sink was always maintained in this compartment. Enzymatic reaction from EN to NA in the samples was stopped by addition of the same volume of acetonitrile.
MATERIALS AND METHODS

Materials and Animals
Preparation of Agar Gel Disc Agar solution of PBS; pH 7.4, prepared at a concentration of 2.5% at 80°C, was poured into a glass dish and sealed with a polyethylene sheet as a liner. The sample was kept at 4°C to form a gel disc 5.0 mm thick and a 2.0 cm in diameter.
In Situ Experiment (1) Insertion of Agar Gel Disc into Rat Abdomen: Two agar gel discs were surgically inserted between the abdominal subcutaneous tissue and the muscle layer in anesthetized hairless rats (1.0 g/kg urethane, i.p.), as described earlier. 13, 16) A horizontally incision along the midline about 5 cm in length was made in the lower portion of the abdominal skin. Discs, each with a glass dish as a backing, were inserted into the left and right abdomen between the hypodermis and the muscle layer (Fig. 1c) . No subcutaneous bleeding was observed after completion of the procedure.
(2) Bolus i.v. Injection: EN or NA in pH 7.4 PBS (17.0 mmol/ml) was injected through the jugular vein at a dose of 34.0 mmol/kg into hairless rats inserted with two agar discs. Blood was sampled at predetermined intervals from the contralateral jugular vein to obtain 100 ml of plasma after centrifugation.
(3) Topical Application: A glass diffusion cell (effective diffusion area, 3.14 cm
2 ) was attached to one side of the skin just above one implanted agar gel disc using cyanoacrylate adhesive (Aron Alpha ® , Konishi, Osaka, Japan). EN aqueous solution (215 mmol/ml, 2.0 ml) was added to the diffusion cell. Blood and agar discs were sampled every 2 h over 6 h and fresh discs were inserted to continue the experiment. The obtained blood was immediately centrifuged to obtain plasma.
In Vivo Experiment (1) Bolus i.v. Injection: EN or NA in pH 7.4 PBS (17.0 mmol/ml) was intravenously injected (2 ml/kg) to hairless rats without agar discs. The time course plasma concentration followed the method described above.
(2) Topical Application: A glass diffusion cell (effective diffusion area, 3.14 cm 2 ) was attached to the abdominal skin surface (the same position as in the in situ experiment) and EN aqueous solution (215 mmol/ml, 2.0 ml) was applied to the diffusion cell in hairless rats without agar discs. After application, blood and agar discs were sampled every 2 h over 6 h.
HPLC Analysis EN and NA were assayed by HPLC with a slight modification of our previously reported method.
8) The HPLC system consists of pump (LC-6A), UV detector (SPD-6A), chromatopac (C-R6A), system controller (SCL-6B) and auto injector (SCL-6B) (whole parts, Shimadzu, Kyoto, Japan), and column (Inertsil ODS 5C18 4.6 mmϫ250 mm, GL Science, Tokyo, Japan). The column temperature was ambient. Mobile phase was 1 mM phosphoric acid : acetonitrileϭ1 : 2. The flow rate of mobile phase was set to 1.0 ml/min and the retention time of NA and EN were 6.2 min and 15.7 min, respectively. Detection was done at UV 260 nm. Quantitation limit of NA and EN were 0.1 mg/ml. Plasma sample containing NA (100 ml) was added to 200 ml of acetonitrile containing ethyl p-oxybenzoate as an internal standard, and the obtained supernatant after centrifugation was injected to HPLC. The agar gel piece containing both EN and NA was added to 200 ml of pH 7.4 PBS containing the internal standard and cut in small pieces. The supernatant obtained after centrifugation of the sample was mixed with the same volume of acetonitrile. The sample was again centrifuged to obtain the supernatant for HPLC injection. Extraction yield assays at three different concentrations of the analyte were preliminarily performed. The mean absolute recovery of both NA and EN from the agar gel in this manner was higher than 95%.
Data Analysis Since the metabolic rate from EN to NA in the body is much faster than that in skin, and elimination pharmacokinetics of NA corresponded to a linear one-compartment model (see Results and Discussion), the cumulative amount of ENϩNA absorbed from the formulation to the systemic circulation over a period of time t, ∑Xb, is as follows:
where CL tot , AUC 0-t , Xb t , Cb t and Vd are total clearance, area under the plasma concentration-time curve from time 0 to t, amount in the central compartment at time t, plasma concentration at time t, and apparent volume of NA distribution, respectively. AUC 0-t was calculated by the trapezoidal rule using the plasma concentration of NA versus time profiles after EN application. The total amount (ENϩNA) migrating from the formulation directly to the application side of the agar gel, ∑Xg direct , can be obtained as the difference between the total amounts on the application and contralateral sides of agar gel discs. Both EN and NA were observed on the application side of the agar gel, whereas only NA was found on the contralateral side (see Results and Discussion). Then,
where ∑Xga and ∑Xgc are the cumulative amount of ENϩNA in the gels on the application and contralateral sides, respectively. EN was not found on the contralateral side of the agar gel, ∑Xgc virtually means the NA amount on the contralateral side. Only NA was found on the contralateral side, the NA amount on the application side migrating from the formulation directly, ∑Xga NAdirect , can be calculated using ∑Xgc as follows.
The total amount of EN and NA that permeated through the skin barrier, ∑X total , is obtained as the sum of the total absorption amount into the systemic circulation, ∑Xb, and direct migration amount of EN and NA into the gel, ∑Xga direct , as follows:
Equations 1 to 4 were used to evaluate the skin disposition and metabolism of topically applied EN. Figure 2 shows plasma concentration profiles of NA after i.v. injection of NA in agar gel discinserted (in situ) and intact hairless rats (in vivo). No significant differences were observed between the in situ and in vivo studies. Only NA was detectable even when the same molarity of EN was injected. Interestingly, almost the same profiles were obtained after injection of EN (data not shown). EN in plasma at first sampling time, 3 min, was under detection. This experimental evidence indicated that the metabolic rate from EN to NA in the systemic circulation was very rapid. Total body clearance (CL tot ) and the apparent volume of distribution (Vd) of NA in in situ and in vivo experiments were calculated as 14.6 and 14.2 ml/h/kg, and 320 and 306 ml/kg, respectively, under the assumption that its elimination kinetics corresponded to the linear one-compartment model. Slightly higher CL tot and Vd values were found in in vivo than in situ, although this difference was not significant. These results were similar to the pharmacokinetics of flurbiprofen reported previously. 13, 16) NA kinetics showed no dose dependency.
RESULTS AND DISCUSSION
I.v. Bolus Injection
In Situ Topical Application Figure 3 (᭹) shows the time course of NA concentration in plasma after topical application of EN (215 mmol/ml, 2.0 ml). EN was not detectable as in the i.v. study due extremely to rapid metabolism from EN to NA in the systemic circulation. Using the elimination parameters of NA and Eq. 1, the cumulative amount of ENϩNA transported from the formulation to the systemic circulation was calculated. Figure 3 (᭺) shows the obtained results. Figures 4a and b show the time course of the cumulative amount (EN, NA and ENϩNA) in the agar gel on the application side and that of NA on the contralateral side, respectively, after topical application of EN. Both EN and NA were detected on the application side, whereas only NA was found on the contralateral side. The amount in Fig. 4b over time t was proportional to the amount of absorption into the systemic circulation (Fig. 3) . This suggested that NA on the contralateral side was derived only from the systemic circulation, and was not due to direct diffusion of EN or NA from the formulation.
The upper part of Table 1 shows EN, NA and their total amounts released from the formulation into the systemic circulation and directly to the application side, calculated using the experimental data shown in Figs. 3, 4 and Eqs. 1 to 4. The values in parentheses show each ratio (%) against the total amount (ENϩNA) that permeated through the stratum corneum. The total amount released from the formulation to the application side was 4.8% (8. 43 mmol) at 6 h, and that into the systemic circulation was 95.2% (167 mmol). This ratio for direct migration to the application side was higher than those of piroxicam and flurbiprofen but lower than that of lidocaine, as shown in our earlier study, 14) taking differences in gel disc size into consideration. Migration ratios over 6 h were 0.0432% (0.0766 mmol), 0.509% (0.902 mmol) and 4.25% (7.52 mmol) for ∑Xgc, ∑Xga EN and ∑Xga NAdirect , respectively. The metabolite ratios (NA/total) on the application side were 89.6, 89.3 and 89.4% at 2, 4 and 6 h, respectively (lower part of Table 2 ). These constant ratios were probably due to the constant permeation rate of EN through the stratum corneum into the viable epidermis and dermis as well as the more rapid metabolic reaction of EN to NA in skin than its diffusion rate across the skin.
The results obtained from these in situ experiments were as follows: Most EN that permeated the skin barrier migrated into the systemic circulation after topical application. All EN and some NA found on the application side came directly from the formulation through the skin and the rest of NA found on the application side was distributed via the systemic circulation. In addition, the metabolite ratio on the application side was markedly high. Figure 5 schematically illustrates the mass balance of EN and NA at 6 h after topical application of EN (calculated from Eqs. 1-4).
In Vivo Topical Application The same topical application experiments of EN were performed in intact rats (data not shown). The time course of NA concentration in plasma and the cumulative amounts of EN and NA transported from the formulation to the systemic circulation after topical application of EN in the in vivo experiments were not significantly different from the in situ data shown in Fig. 3 , suggesting that the insertion of agar gel discs into the rat abdomen had little effect. The rate of metabolism of EN to NA in the systemic circulation was so fast that the metabolite ratio in skin could not be determined by their plasma concentration profiles. Direct measurement of the skin levels was not performed in this experiment.
In Vitro Skin Permeation Experiments Figure 6 shows the in vitro skin permeation profiles of EN, NA and this sum. The total amount of skin permeation for the in vitro experiment was a little lower than the total amounts that migrated into the systemic circulation in situ (Fig. 3) and in vivo. This was probably due to a longer diffusion path length in the excised rat skin for the in vitro experiment than in in situ and in vivo studies. 12) The metabolite ratio in skin was not determined from plasma data in the in situ study similarly to the in vivo study, Values in parentheses show each ratio (%) against total amount (ENϩNA) that permeated through the stratum corneum. and the metabolite ratio on the application side was used as an index. The index was compared with the metabolite ratio in receiver solution in the in vitro permeation study. The data are summarized in Table 2 . The in situ metabolite ratios were higher than those in vitro for each sampling time point. This difference may be explained by the existence or absence of drug uptake from cutaneous vessels. The vessels generally take up most drugs that permeate the upper dermis in vivo and in situ. Since EN is more lipophilic than NA, uptake by the cutaneous vessels of EN may be higher than that of NA, leading to a lower metabolite ratio in situ.
CONCLUSIONS
The present results suggested that the agar gel disc-inserted in situ rat model is useful to evaluate the skin disposition and metabolism of topically applied EN. The skin disposition in the in situ model is similar to the in vivo profile, since the role of cutaneous vessels is included. The present in situ method was also utilized to determine the metabolite ratio as in the in vitro permeation experiment. This in situ model is therefore useful for analysis of the dermato-pharmacokinetics of drugs, since it has the advantages of in vivo and in vitro experiments without their minor drawbacks. This in situ model may fill the gap between in vitro and in vivo models. 
